Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
166 studies found for:    prodrugs

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Withdrawn Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer
Condition: Breast Neoplasm
Intervention: Drug: Aminoflavone Prodrug
2 Completed Bioavailability Study of Prodrug of GLPG0187 in Healthy Volunteers
Condition: Healthy
Intervention: Drug: GLPG0187 prodrug
3 Completed Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects
Conditions: Pharmacokinetics of 14C-labeled Isavuconazole;   Healthy Subjects
Intervention: Drug: 14C-labeled prodrug isavuconazonium sulfate
4 Completed Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects
Condition: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Interventions: Drug: 5 mg ACT-281959 prodrug formulation I (Group A);   Drug: 20 mg ACT-281959 prodrug formulation I (Group B);   Drug: ACT-281959 prodrug formulation I (Groups C to G doses to be defined);   Drug: ACT-281959 prodrug formulation II (Group G dose to be defined);   Drug: ACT-246475 (Group G dose to be defined);   Drug: Placebo (Groups A to F)
5 Completed Safety and Effectiveness of Adding PMPA Prodrug to an Anti-HIV Drug Combination to Treat HIV-Infected Patients
Condition: HIV Infections
Intervention: Drug: Tenofovir disoproxil fumarate
6 Recruiting Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.
Conditions: Cancer;   Solid Tumor;   Metastatic Colorectal Cancer (mCRC)
Intervention: Drug: Promitil
7 Completed A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
Condition: Healthy
Interventions: Drug: BCI-838;   Drug: BCI-1038, BCI-1206 & BCI-1283
8 Recruiting A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Conditions: Malignant Glioma;   Recurrent Ependymoma
Interventions: Biological: AdV-tk;   Drug: valacyclovir;   Radiation: Radiation
9 Recruiting Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Conditions: Kidney Cancer;   Liver Cancer
Interventions: Drug: hypoxia-activated prodrug TH-302;   Drug: sorafenib tosylate;   Genetic: protein analysis;   Other: laboratory biomarker analysis
10 Unknown † The Safety and Effectiveness of PMPA Prodrug in HIV-Infected Patients
Condition: HIV Infections
Intervention: Drug: Tenofovir disoproxil fumarate
11 Completed A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Condition: Hepatitis C, Chronic
Interventions: Drug: Copegus;   Drug: PEGASYS;   Drug: RO5024048
12 Completed A Study of HCV Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
Condition: Hepatitis C, Chronic
Interventions: Drug: Copegus;   Drug: Pegasys;   Drug: RO4588161
13 Completed Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   High-risk Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Advanced Myelofibrosis
Intervention: Drug: TH-302
14 Completed A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048
Condition: Healthy Volunteer
Intervention: Drug: RO5024048
15 Completed Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.
Condition: Healthy
Interventions: Drug: BIBR 1048 MS polymorph II;   Drug: BIBR 1048 MS polymorph I
16 Completed A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
Conditions: Cytomegalovirus Retinitis;   HIV Infections
Intervention: Drug: Valganciclovir
17 Unknown † A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine
18 Completed Safety Study to Evaluate BMS-830216 in Healthy Subjects
Condition: Obesity
Interventions: Drug: BMS-830216;   Drug: Placebo
19 Completed A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or Without Cystic Fibrosis.
Condition: Cytomegalovirus Infections
Intervention: Drug: valganciclovir [Valcyte]
20 Unknown † Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease
Condition: Chronic Chagas Disease, Indeterminate
Interventions: Drug: E1224;   Drug: Benznidazole;   Drug: Placebo
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years